Surrey Heartlands

Joint Formulary & PAD

Alprostadil - Erectile dysfunction

You are here : Home > Formulary Search > Alprostadil - Erectile dysfunction

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Cream
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
R
Restrictions / Comments :
Important
Only in patients who do not respond to PDE-5 inhibitors.
Documents :
 
Evidence Review
Alprostadil cream - Evidence review - Sep 2015
 

Status 2

Blue
Formulations :
  • Intraurethral
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Patient to be provided with training materials prior to request for primary care prescribing.
 

Status 3

Blue
Formulations :
  • Intracavernosal injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Restrictions / Comments :
Important
Initiation and assessment of efficacy prior to transfer to primary care.

Documentation

Information
Erectile dysfunction - traffic light status updates - Jun 2024

PAD Profile

ChemicalSubstance :
Alprostadil
Indication :
Erectile dysfunction
Group Name :
Keywords :
ED, impotence, urethral stick
Brand Names Include :
Vitaros, MUSE, Caverject, Viridal Duo
Important Information :
Treatments for ED on the NHS require an SLS endorsement.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Erectile dysfunction
Supporting Documents :
2
Traffic Light Entries :
3

Other Indications

Below are listed other indications that Alprostadil is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Erectile dysfunction.

Committee Recommendations (1)

05 Jun 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Alprostadil intra-urethral applications may be initiated in primary care following specialist recommendation.

The patient must have been provided with, or directed to, training materials to support self-administration before prescribing is requested from the GP.

Alprostadil intracavernosal injections should be initiated in secondary care, patients trained to self-administer and treatment shown to be effective before discharge for GPs to prescribe.

Alprostadil cream (Vitaros) is restricted by SLS criteria as identified in the Health Service Circular (HSC) 1999/148 at a maximum frequency of dosing of four times per month.

Alprostadil cream (Vitaros®) is a treatment option in primary care for patients who do not respond to PDE-5 inhibitors. This can be initiated in primary care and is considered GREEN on the traffic light system

Combination treatments (oral & non oral)
These treatments should not be used in combination with other treatments for erectile dysfunction due to the limited evidence available to support their use.